Skip to main content

Table 1 Inclusion and exclusion study criteria

From: Evaluation of the protective efficacy of a spatial repellent to reduce malaria incidence in children in Mali compared to placebo: study protocol for a cluster-randomized double-blinded control trial (the AEGIS program)

Inclusion criteria

Exclusion criteria

Children ≥ 6 months to < 10 years of age

Children ≤ 6 months to > 10 years of age

Children with Hb ≥ 7 g/dL and no other serious illness

Children with Hb < 7 g/dL with signs of known chronic disease or other serious illness, or Hb < 6 g/dL with signs of clinical decompensation

Sleeps in cluster > 90% of nights during any given month

Sleeps in cluster < 90% of nights during any given month

Not participating in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the trial

Participating or planned participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the trial

Provision of informed consent form (ICF) signed by the parent(s) or guardian

No provision of ICF signed by the parent(s) or guardian